InsiderSignalSign in

← Insider buys

BVF PARTNERS L P/IL has bought stock on 67 days since Jan 2016

See Remarks and Footnotes at Kymera Therapeutics, Inc., and 22 other companies

SEC CIK 0001055947 · Filings on SEC.gov ↗

$276.2MBought

$990.1MSold

Jul 1Last buy

BVF PARTNERS L P/IL's record

3 months after each buy, from the first price a copier could get.

+28.5%Average

+24.9 ptsVs S&P 500

14 of 19Higher

19 buys since 2016 with 3 months of prices.

Companies

Every filing

94 filings since Jan 2016, newest first

Kymera Therapeutics, Inc.

See Remarks and Footnotes

$173.7M−95.4%Jun 26

Moonlake Immunotherapeutics

Director and 10% owner

$63.0M−78.0%Apr 2

Kymera Therapeutics, Inc.

See Remarks and Footnotes

$14.0M+875.0%Jul 1

Third Harmonic Bio, Inc.

Insider

$14.3M−85.0%Oct 31

Moonlake Immunotherapeutics

Director and 10% owner

$100.0M−61.0%Oct 8

Point Biopharma Global Inc.

Former 10% Owner

$213.7M−100.0%Dec 20

Kymera Therapeutics, Inc.

See Remarks and Footnotes

$5.3M−347.0%Nov 6

Repare Therapeutics Inc.

10% owner

$2.8M−262.0%Nov 3

Olema Pharmaceuticals, Inc.

Director and 10% owner

$14.8M−171.0%Sep 14

Kymera Therapeutics, Inc.

See Remarks and Footnotes

$1.3M+2.0%Jan 13

Xoma Corp

10% owner

$421K+1.0%Jan 9

Xoma Corp

10% owner

$409K+1.0%Sep 27

Xoma Corp

10% owner

$991K+3.0%Sep 16

Kymera Therapeutics, Inc.

See Remarks and Footnotes

$14.2M−190.0%Aug 23

Cti Biopharma Corp

10% owner

$52.0M−79.0%Aug 11

Repare Therapeutics Inc.

10% owner

$21.9M−128.0%Jun 6

Cullinan Oncology, Inc.

10% owner

$8.3M−194.0%Jun 3

Cullinan Oncology, Inc.

10% owner

$10.1M−140.0%May 16

Kymera Therapeutics, Inc.

See Remarks and Footnotes

$4.9M−752.0%May 9

Cullinan Oncology, Inc.

10% owner

$3.0M+12.0%Apr 5

Repare Therapeutics Inc.

10% owner

$14.1M−145.0%Jan 21

Olema Pharmaceuticals, Inc.

Director and 10% owner

$6.9M−276.0%Dec 2

Merus N.V.

10% owner

$31.2M−83.0%Oct 8

Merus N.V.

10% owner

$45.4M−88.0%Jul 7

Cti Biopharma Corp

10% owner

$5.0M−1160.0%Apr 5

Xoma Corp

10% owner

$25.0M−60.0%Apr 2

Merus N.V.

10% owner

$5.9M+185.0%Apr 1

Merus N.V.

10% owner

$1.8M+3.0%Mar 24

Merus N.V.

10% owner

$5.7M+141.0%Mar 18

Ideaya Biosciences, Inc.

Insider

$835K−17.0%Feb 4

Infinity Pharmaceuticals, Inc.

10% owner

$24.2M−89.0%Jan 26

Merus N.V.

10% owner

$20.9M−202.0%Jan 25

Merus N.V.

10% owner

$2.6M+6.0%Dec 22

Xoma Corp

10% owner

$5.0M+5.0%Dec 15

Cytokinetics Inc

Insider

$7.8M−48.0%Dec 11

Olema Pharmaceuticals, Inc.

Director and 10% owner

$21.6M−162.0%Nov 20

Five Prime Therapeutics, Inc.

Insider

$149.2M−99.0%Nov 13

Five Prime Therapeutics, Inc.

10% owner

$2.2M+325.0%Nov 6

Glycomimetics Inc

10% owner

$3.3M−199.0%Nov 6

Glycomimetics Inc

10% owner

$2.6M−240.0%Nov 3

Merus N.V.

10% owner

$2.3M+128.0%Sep 8

Xoma Corp

10% owner

$666K+2.0%Sep 1

Xoma Corp

10% owner

$547K+1.0%Aug 25

Xoma Corp

10% owner

Xoma Corp

10% owner

$499K+1.0%Aug 14

Ideaya Biosciences, Inc.

10% owner

Calithera Biosciences, Inc.

10% owner

$13.7M−83.0%May 26

Five Prime Therapeutics, Inc.

10% owner

$1.2M+119.0%May 18

Xoma Corp

10% owner

Xoma Corp

10% owner

About BVF PARTNERS L P/IL

BVF Partners L.P./IL is a biotechnology-focused investment firm and corporate insider that holds significant positions in multiple life sciences companies, including Kymera Therapeutics, Inc. (NASDAQ: KYMR).( At Kymera, BVF Partners and its affiliated funds are reported as a major shareholder and director by deputization, reflecting board representation through a BVF member and coordinated ownership across entities such as Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., and BVF Partners OS Ltd.( BVF Partners L.P. is listed on Kymera’s insider roster as an affiliated person/insider and 10% beneficial owner through these funds.(

BVF Partners operates as a specialist biotechnology investment partnership, often filing as a group with related general partner entities (BVF I GP LLC, BVF II GP LLC, BVF GP Holdings LLC, BVF Inc) and principal Mark N. Lampert, who is widely associated with the Biotechnology Value Fund platform.( The firm actively manages sizable positions across public biotech companies and is tracked in regulatory filings for substantial insider trading activity, including large purchases and sales in Kymera Therapeutics and other issuers.( Its leadership and operations center on value-driven investing in biotechnology, using pooled limited partnership structures and affiliated vehicles to build concentrated positions and exercise governance influence through board representation and coordinated insider filings.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.